Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5LEOR)

• Drug Name: JNJ-28583867 Drug Info
• Synonyms: JNJ-28583867; CHEMBL257917

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44456154
  TTD Drug ID: DM5LEOR

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[3]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[4]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[5]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[7]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[8]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[4]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[4]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[4]

Drug(s) Targeting Histamine H3 receptor (H3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pitolisant	DM8RFNJ	Excessive daytime sleepiness	MG42	Approved	[9]
SUVN-G3031	DM3BO8G	Cognitive impairment	6D71	Phase 3	[10]
JNJ-17216498	DM1GRCU	Narcolepsy	7A20	Phase 2	[11]
GSK239512	DMBJMZC	Alzheimer disease	8A20	Phase 2	[12]
JNJ-39220675	DM0WY3H	Alcohol dependence	6C40.2	Phase 2	[13]
AZD-5213	DMOZ04X	Alzheimer disease	8A20	Phase 2	[14]
Bavisant	DM6CVZ5	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[15]
ABT-288	DM7X54F	Alzheimer disease	8A20	Phase 2	[16]
SAR-110894	DMCLEXM	Alzheimer disease	8A20	Phase 2	[14]
ABT-652	DMLEO2Z	Diabetic neuropathy	8C0Z	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H3 receptor (H3R)	TT9JNIC	HRH3_HUMAN	Inhibitor	[1]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):39-43.
• [2] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [3] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [6] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [7] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [8] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
• [12] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [13] JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
• [14] SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
• [15] Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
• [16] A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)